Treated mice showed tumor inhibition comparable to that achieved with sorafenib, and HCC tissues from the miR-199a-treated group exhibited reduced mTOR and PAK4 protein expression [27]. This evidence concerns the gene PAK4 and hepatocellular carcinoma.